abstract |
The present invention provides an ophthalmic formulation having a high concentration of vascular endothelial growth factor (VEGF) receptor fusion protein and having high stability during storage. In addition, there is provided a method for treating an eye disorder of vascular origin using a high concentration of the agent. |